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Clinical and neurobiological ﬁndings suggest that the cannabinoids and the endocannabi-
noid system may be implicated in the pathophysiology and treatment of schizophrenia.We
described that the spontaneously hypertensive rats (SHR) strain presents a schizophrenia
behavioral phenotype that is speciﬁcally attenuated by antipsychotic drugs, and potentiated
by proschizophrenia manipulations. Based on these ﬁndings, we have suggested this
strain as an animal model of schizophrenia. The aim of this study was to evaluate the
effects of cannabinoid drugs on the deﬁcit of prepulse inhibition (PPI) of startle, the
main paradigm used to study sensorimotor gating impairment related to schizophrenia,
presented by the SHR strain.The following drugs were used: (1)WIN55212,2 (cannabinoid
agonist), (2) rimonabant (CB1 antagonist), (3) AM404 (anandamide uptake inhibitor), and
(4) cannabidiol (CBD; indirect CB1/CB2 receptor antagonist, among other effects). Wistar
rats (WRs) and SHRs were treated with vehicle (VEH) or different doses of WIN55212
(0.3, 1, or 3 mg/kg), rimonabant (0.75, 1.5, or 3 mg/kg), AM404 (1, 5, or 10 mg/kg), or
CBD (15, 30, or 60 mg/kg). VEH-treated SHRs showed a decreased PPI when compared
to WRs. This PPI deﬁcit was reversed by 1 mg/kg WIN and 30 mg/kg CBD. Conversely,
0.75 mg/kg rimonabant decreased PPI in SHR strain, whereas AM404 did not modify it.
Our results reinforce the role of the endocannabinoid system in the sensorimotor gating
impairment related to schizophrenia, and point to cannabinoid drugs as potential therapeutic
strategies.
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INTRODUCTION
Prepulse inhibition (PPI) of startle is characterized by the reduc-
tion of an acoustic startle reﬂex to an intense acoustic stimulus
(pulse) when immediately preceded by a lower intensity stimulus
(prepulse; Swerdlow et al., 2001). PPI is considered an opera-
tional measure of sensorimotor gating, and is extensively used
in translational models of psychosis since it appears to be present
in all mammals, including rats and humans (Swerdlow et al., 1994,
2000), and is disrupted in schizophrenia patients (Braff and Geyer,
1990; Braff et al., 1992, 1999; Weike et al., 2000).
The spontaneously hypertensive rat (SHR) strain was devel-
oped by selecting brother–sister mating Wistar rats (WRs) with a
hypertensive phenotype (Okamoto and Aoki, 1963). Along with
the hypertension presented by these animals, the inbreeding also
selected behavioral abnormalities that lead to suggest them as a
putative animal model of attention deﬁcit/hyperactivity disor-
der (Sagvolden and Sergeant, 1998; Russell, 2007). This strain
presents sustained attention problems, hyperactivity in a variety
of behavioral paradigms and impulsivity (Sagvolden et al., 1992;
Russell, 2007). Nevertheless, the absence of beneﬁcial effects of
psychostimulants (used to treat this disorder) on these behaviors in
adult SHRs (van den Bergh et al., 2006; Bizot et al., 2007; Calzavara
et al., 2009) has been described. In fact, some behavioral changes
are even potentiated by these drugs (Calzavara et al., 2009). It is
noteworthy thatmost of the studies using the SHR strain to investi-
gate attention deﬁcit/hyperactivity disorder were performed using
the Wistar-Kyoto strain (WKY – developed by inbreeding WRs
without hypertension) as controls, which may be unsuitable since
it has been reported that WKY animals present an inactivity when
compared toWRs (Pare, 1992, 1994), and donot show genetic sim-
ilarities when compared to the SHR strain (Johnson et al., 1992;
St Lezin et al., 1992).
Recently, our group has reported that the SHR strain, when
compared to WRs, presents many behavioral changes that are
speciﬁcally reversed by antipsychotic drugs and potentiated by
proschizophrenia manipulations. Particularly, this strain displays
impaired social interaction (mimics negative symptoms) that
is speciﬁcally ameliorated by atypical antipsychotics and aggra-
vated by amphetamine (Calzavara et al., 2011), hyperlocomotion
(mimics positive symptoms) attenuated by antipsychotics and
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potentiated by amphetamine (Calzavara et al., 2011) and a
deﬁcit in contextual fear conditioning (CFC – model of emo-
tional processing) that is reversed speciﬁcally by antipsychotics
and potentiated by psychostimulants or other proschizophre-
nia manipulations, such as ketamine administration and sleep
deprivation (Calzavara et al., 2009). Moreover, this strain has
a basal PPI deﬁcit speciﬁcally reverted by the atypical antipsy-
chotic clozapine (Levin et al., 2011). These ﬁndings rein-
force the SHR strain as an animal model to study several
aspects of schizophrenia, including abnormalities in sensorimotor
gating.
It is noteworthy that previous studies describe controversial
results in relation to PPI in SHRs using control strains other
than the WRs. Some studies show that SHRs present PPI deﬁcits
when compared toWKY (Ferguson andCada, 2004; Kinkead et al.,
2006), to Sprague-Dawley (SD; Ferguson and Cada, 2004), or to
Lewis rats (Vendruscolo et al., 2006). Conversely, other studies
demonstrate that PPI tended to be higher in SHRs and WKY than
in SD rats (van den Buuse, 2004), or that SHRs have intermediate
PPI values (Brown-Norway < SHR < SD < WKY – Palmer et al.,
2000).
Several clinical and neurobiological ﬁndings suggest that some
cannabinoids and the endocannabinoid system may be implicated
in schizophrenia (Leweke et al., 2004; D’Souza et al., 2009). Some
studies suggest that cannabis abuse is a method of self-medication
for negative symptoms of the disease (Peralta and Cuesta, 1992;
Bersani et al., 2002), or side effects of antipsychotics (Krystal et al.,
1999; Verdoux et al., 2005). Other studies report that cannabis
consumption may induce a psychotic state in normal individu-
als, worsen psychotic symptoms of schizophrenia patients, and
facilitate precipitation of schizophrenia in vulnerable individu-
als (Ujike and Morita, 2004; Sewell et al., 2010). In postmortem
studies, schizophrenia patients showed an increased density of
the cannabinoid CB1 receptor binding in corticolimbic regions
involved in this disorder (Dean et al., 2001; Zavitsanou et al.,
2004; Newell et al., 2006; Dalton et al., 2011), indicating their
role in negative symptoms and cognitive impairments (Gallinat
et al., 2012). Moreover, elevated anandamide levels in the cere-
brospinal ﬂuid (Leweke et al., 2007; Koethe et al., 2009) and plasma
(De Marchi et al., 2003) of patients with schizophrenia have been
described.
Recently, we have demonstrated that CBD – a non-
psychotomimetic compound of the Cannabis sativa plant that
presents antipsychotic properties (Zuardi et al., 2012) – and
rimonabant – a CB1 receptor antagonist (Rinaldi-Carmona et al.,
1994) – were able to reverse the deﬁcit in CFC task presented by
SHRs. These results suggest that these drugs could constitute an
alternative for the treatment of abnormalities in emotional context
processing related to schizophrenia (Levin et al., 2012).
In order to further investigate the potential of the endocannabi-
noid system as target for the treatment of schizophrenia, the aim
of this study was to evaluate the effects of cannabinoid drugs on
the deﬁcit of PPI presented by the SHR strain. For this purpose,
dose–response curves of the following drugs were investigated:
WIN55212,2 (cannabinoidagonist), rimonabant (CB1 antago-
nist), AM404 (anandamide uptake inhibitor), and CBD (indirect
CB1/CB2 receptor antagonist, among other effects).
MATERIALS AND METHODS
ANIMALS
Five-month-old, male WRs and SHRs of our own colony were
housed under conditions of controlled temperature (22–23◦C)
and lighting (12/12 h light/dark cycle, lights on at 07:00
am). Groups of ﬁve animals were kept in Plexiglas cages
(41 cm × 34 cm × 16.5 cm), with free access to food and water.
The animals were maintained in accordance with the guidelines of
the Committee on Care and Use of Laboratory Animal Resources,
National Research Council, USA. This study was approved by the
Ethical Committee of Federal University of Sao Paulo. All rats used
were drug-naive before each experiment.
DRUGS
WIN55212,2 (Tocris) and CBD (THC-Pharm, Frankfurt, Ger-
many andSTI-Pharm,Brentwood,UK)weredissolved inTween80
and 0.9% saline. Rimonabant (Sanoﬁ-Aventis®) was dissolved in
ethanol, Tween 80 and 0.9% saline (ratio 1:1:18). AM404 (Tocris)
was dissolved in Dimethyl Sulfoxide (DMSO) and Tween 80 and
then diluted in 0.9% saline. Control solutions consisted of saline
plus Tween 80, DMSO or ethanol, depending on the drugs used in
each experiment. All drug solutionswere injected intraperitoneally
(i.p.) in a volume of 1 ml/kg body weight.
APPARATUS
The rats were placed in a stabilimeter, which consisted of a wire-
mesh cage (16.5 cm × 5.1 cm × 7.6 cm) suspended within a
polyvinyl chloride frame (25 cm × 9 cm × 9 cm) attached to
the response platform with four thumbnail-screws. The stabilime-
ter and platform were located inside a ventilated plywood sound
attenuating chamber (64 cm × 60 cm × 40 cm). The ﬂoor of the
stabilimiter consisted of six stainless steel bars 3.0 mm in diameter
and spaced 1.5 cm apart. The startle reaction of the rats gen-
erated a pressure on the response platform and analog signals
were ampliﬁed, digitized, and analyzed by software of the startle
measure system (Insight, São Paulo, Brazil), that also controlled
other parameters of the session (intensity of the acoustic stimu-
lus, inter-stimulus interval, etc). Two loudspeakers located 10 cm
above the ﬂoor, on each lateral side of the acoustic isolation cham-
ber, were used to deliver the prepulse stimulus, the acoustic startle
stimulus, and continuous background noise. Calibration proce-
dures were conducted before the experiments to ensure equivalent
sensitivities of the response platforms over the test period.
PPI TESTING
The PPI testing began 30 min after the injection, by placing
each animal in the stabilimeter cage where they were exposed
to a background (65 dB) noise for 5 min. After this acclimati-
zation period, the rats were submitted to a series of 10 stimuli
(pulse alone – 120 dB, 50 ms duration), with an average inter-
trial interval of 20 s. The purpose of this phase was to allow
within-session habituation (not calculated herein) to the star-
tle stimulus, and was not included in the calculation of PPI
values nor of acoustic startle response (ASR). Thereafter, the
PPI modulation of the acoustic startle was tested: this phase
consisted of pseudorandomly delivered trials divided into four
different categories presented with an average inter-trial interval
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of 20 s: 20 presentations of pulse alone (120 dB, 50 ms dura-
tion), 8 presentations of each prepulse alone (70, 75, and 80 dB,
3000 Hz frequency, 20 ms duration), 10 presentations of each pre-
pulse + pulse (with 100 ms interval), and 8 no-stimulus trials
(stabilimeter recordings obtained when no stimulus was pre-
sented). Mean amplitude of startle responses to pulse-alone (P)
and prepulse-pulse (PP + P) trials was calculated for each sub-
ject. The level of PPI in each rat was determined by expressing the
prepulse + pulse startle amplitude as a percentage decrease from
pulse-alone startle amplitude, according to the following formula:
%PPI = 100 − [100 × (PP/P)]. The ASR was expressed as the
average of the 20 P trials.
All rats were submitted to a previous PPI session without drug
administration. After this session, called “matching” (Swerdlow
et al., 2005), rats were distributed into pharmacological groups
[vehicle (VEH) or drug, for each experiment] matched for
basal %PPI. Seven days later, each rat was submitted to a test
session.
STATISTICAL ANALYSIS
The ASR results were analyzed by two-way ANOVA (strain
X treatment). The %PPI data were analyzed by three-way
ANOVA with treatment and strain as between-subjects fac-
tors and prepulse intensity as within-subject factor. Since no
interaction between strain and prepulse intensity, or treatment
and prepulse intensity were detected, the post hoc compari-
son was then performed with the mean %PPI for the three
prepulse intensities. Moreover, when an interaction between
treatment and strain were detected, the data from each strain
was analyzed separately. All post hoc comparisons were per-
formed using Dunnett’s test, with VEH treatment as the control
condition.
It is known that ASR might inﬂuence %PPI (Csomor et al.,
2008). In this sense, the %PPI results were also analyzed by three-
way repeated measures analysis of covariance (ANCOVA) with
ASR as covariant (as suggested by Csomor et al., 2008), treatment
and strain as between-subjects factors and prepulse intensity as
within-subject factor. If a difference detected onANOVAremained
signiﬁcant on ANCOVA, it is possible to state that the difference
was not solely due to inﬂuences of ASR. The p < 0.05 was used
as criterion for statistical signiﬁcance. All statistical analyses were
conducted on the software SPSS 20.
EXPERIMENTAL DESIGN
Experiment 1: effect of WIN55212,2 (cannabinoid agonist) on %PPI
and ASR of WRs and SHRs
Wistar rats and SHRs were treated with VEH, 0.3, 1, or
3 mg/kg WIN 55212,2 (WIN; n = 10, per strain and treat-
ment). Thirty minutes later, the rats were submitted to the PPI
test.
Experiment 2: effect of rimonabant (CB1antagonist) on %PPI and
ASR of WRs and SHRs
Wistar rats and SHRs were treated with VEH or 0.75, 1.5, or
3 mg/kg rimonabant (RIMO; n = 9–11, per strain and treat-
ment). Thirty minutes later, the animals were submitted to the PPI
test.
Experiment 3: effect of AM404 (anandamide uptake inhibitor) on
%PPI and ASR of WRs and SHRs
Wistar rats and SHRs were treated with VEH or 1, 5, or 10 mg/kg
AM404 (AM; n = 9–11, per strain and treatment). Thirty minutes
later, the animals were submitted to the PPI test.
Experiment 4: effect of cannabidiol (a cannabinoid with
antipsychotic property) on %PPI and ASR of WRs and SHRs
Wistar rats and SHRswere treatedwithVEHor 15, 30, or 60mg/kg
CBD (n = 9–10, per strain and treatment). Thirty minutes later,
the animals were submitted to the PPI test. In all the experiments,
each animal was used for only one drug condition.
RESULTS
EXPERIMENT 1: EFFECT OF WIN 55212,2 (CANNABINOID AGONIST) ON
%PPI AND ASR OF WRs AND SHRs
Two-wayANOVA showed only a signiﬁcant effect of strain onASR
[F(1,72) = 31.93; p < 0.001]. WRs presented a higher ASR when
compared to SHRs (Table 1).
Three-way repeated measures ANOVA revealed signiﬁcant
effects of prepulse intensity (reﬂecting that the more intense the
prepulse, the higher the PPI) [F(2,144) = 26.65; p < 0.001], strain
(reﬂecting a decreased PPI in SHRs) [F(1,72) = 18.87; p < 0.001],
and an interaction between strain and treatment [F(3,72) = 3.15,
p = 0.030] on %PPI. Neither treatment nor interactions between
%PPI and treatment or strain reached signiﬁcance. All the effects
detected on ANOVA remained signiﬁcant on ANCOVA. Post hoc
analysis showed that treatment with 1 mg/kg WIN increased %
PPI in SHRs (p = 0.035; Figure 1).
EXPERIMENT 2: EFFECT OF RIMONABANT (CB1 ANTAGONIST) ON %PPI
AND ASR OF WRs AND SHRs
Two-wayANOVA showed only a signiﬁcant effect of strain onASR
[F(1,75) = 19.71; p < 0.001]. WRs presented a higher ASR when
compared to SHRs (Table 1).
Three-way repeated measures ANOVA showed signiﬁcant
effects of prepulse intensity (reﬂecting that the more intense the
prepulse, the higher the PPI) [F(2,150) = 53.45; p < 0.001],
strain (reﬂecting a decreased PPI in SHRs) [F(1,75) = 32.50;
p < 0.001] and an interaction between strain and treatment
[F(3,75) = 7.26, p < 0.001] on %PPI. Neither treatment nor
interactions between %PPI and treatment or strain reached sig-
niﬁcance. All the effects detected on ANOVA remained signiﬁcant
on ANCOVA. Post hoc analysis showed that that treatment with
0.75 mg/kg RIMO decreased %PPI in SHRs (p = 0.017; Figure 2).
EXPERIMENT 3: EFFECT OF AM404 (ANANDAMIDE UPTAKE INHIBITOR)
ON %PPI AND ASR OF WRs AND SHRs
Two-wayANOVA showed only a signiﬁcant effect of strain onASR
[F(1,72) = 37.48; p < 0.001]. WRs presented a higher ASR when
compared to SHRs (Table 1).
Three-way repeated measures ANOVA showed signiﬁcant
effects of prepulse intensity (reﬂecting increased PPI by increasing
the intensity of prepulse) [F(2,144) = 10,89; p < 0.001] and strain
(reﬂecting a decreased PPI in SHRs) [F(1,72) = 31.23; p < 0.001].
Neither treatment nor any possible interaction with this factor
reached signiﬁcance (reﬂecting that there was no effect of AM404
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Table 1 | Acoustic startle response (ASR) ofWistar rats (WRs) and spontaneously hypertensive rats (SHRs) treated with vehicle (VEH), 0.3, 1, or
3 mg/kgWIN55212,2 (WIN – Experiment 1);VEH, 0.75, 1.5, or 3 mg/kg rimonabant (RIMO – Experiment 2);VEH, 1, 5, or 10 mg/kg AM404
(AM – Experiment 3);VEH, 15, 30, or 60 mg/kg cannabidiol (CBD – Experiment 4).
Experiment 1 VEH WIN 0.3 WIN 1 WIN 3
WRs 464.6 ± 107.3 (n = 10) 422.3 ± 161.4 (n = 10) 588.3 ± 151.4 (n = 10) 588 ± 176.9 (n = 10)
SHRs 87.8 ± 10.7* (n = 10) 82.3 ± 10.7* (n = 10) 87.6 ± 15.1* (n = 10) 82.5 ± 27.3* (n = 10)
Experiment 2 VEH RIMO 0.75 RIMO 1.5 RIMO 3
WRs 491.2 ± 109.3 (n = 11) 477.3 ± 138.8 (n = 11) 534.4 ± 144.1 (n = 11) 158.6 ± 76.3 (n = 11)
SHRs 198.7 ± 115.1* (n = 9) 71.1 ± 9.4* (n = 10) 140.5 ± 31.1* (n = 11) 85.2 ± 8.6* (n = 10)
Experiment 3 VEH AM 1 AM 5 AM 10
WRs 478.0 ± 136.3 (n = 10) 539.6 ± 157.0 (n = 9) 613.2 ± 126.9 (n = 10) 450.7 ± 125.8 (n = 10)
SHRs 127.2 ± 13.8* (n = 10) 135.3 ± 27.9* (n = 11) 76.0 ± 10.6* (n = 10) 100.0 ± 23.2* (n = 10)
Experiment 4 VEH CBD 15 CBD 30 CBD 60
WRs 486.2 ± 188.3 (n = 10) 239.6 ± 98.2 (n = 9) 234.3 ± 56.6 (n = 10) 343.7 ± 72.3 (n = 10)
SHRs 92.5 ± 8.2* (n = 10) 76.1 ± 8.5* (n = 10) 117.4 ± 13.6* (n = 10) 57.1 ± 6.9* (n = 10)
*p < 0.001 compared to WRs. Two-way ANOVA. Data are reported as mean ± SE.
FIGURE 1 | %PPI ofWistar rats (WRs) and spontaneously hypertensive
rats (SHRs) treated with vehicle (VEH), 0.3, 1, or 3 mg/kgWIN55212,2
(WIN). *p < 0.001 compared toWRs. #p < 0.05 compared to VEH group of
the same strain. Three-way repeated measures ANOVA followed by
Dunnett’s test. Data are reported as mean ± SE.
on %PPI in any of the strains). All the effects detected on ANOVA
remained signiﬁcant on ANCOVA. (Figure 3).
EXPERIMENT 4: EFFECT OF CANNABIDIOL (A CANNABINOID WITH
ANTIPSYCHOTIC PROPERTY) ON %PPI AND ASR OF WRs AND SHRs
Two-wayANOVA showed only a signiﬁcant effect of strain onASR
[F(1,71) = 17.27; p < 0.001]. WRs presented a higher ASR when
compared to SHRs (Table 1).
Three-way repeated measures ANOVA showed signiﬁcant
effects of prepulse intensity (reﬂecting increased PPI by increasing
the intensity of prepulse) [F(2,142) = 13.83; p < 0.001], strain
(reﬂecting a decreased PPI in SHRs) [F(1,71) = 41.08; p < 0.001]
and treatment [F(3,71) = 5.99; p = 0.001]. None of the inter-
actions between these factors reached signiﬁcance. All the effects
detected on ANOVA remained signiﬁcant on ANCOVA. Post hoc
FIGURE 2 | %PPI ofWistar rats (WRs) and spontaneously hypertensive
rats (SHRs) treated with vehicle (VEH), 0.75, 1.5, or 3 mg/kg
rimonabant (RIMO). *p < 0.001 compared toWRs. #p < 0.05 compared
to VEH group of the same strain. Three-way repeated measures ANOVA
followed by Dunnett’s test. Data are reported as mean ± SE.
analysis revealed that treatment with 30 mg/kg CBD increased PPI
response (p = 0.020; Figure 4).
DISCUSSION
Our data show that SHRs have deﬁcits in baseline PPI (corrobo-
rating previous data from our group – Levin et al., 2011) and ASR
when compared to WRs. These ﬁndings are in accordance with
clinical studies in schizophrenia which show disrupted PPI (Braff
and Geyer, 1990; Braff et al., 1992, 1999; Weike et al., 2000), and
lower startle reactivity (Quednow et al., 2006, 2008 – but see Gril-
lon et al., 1992; Weike et al., 2000; Xue et al., 2012 and comments
on the possible reasons for these negative results inQuednow et al.,
2006) when compared to controls, and reinforce the SHR strain
as an animal model to study abnormalities in sensorimotor gating
related to schizophrenia.
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FIGURE 3 | %PPI ofWistar rats (WRs) and spontaneously hypertensive
rats (SHRs) treated with vehicle (VEH), 1, 5, or 10 mg/kg AM404 (AM).
*p < 0.001 compared toWRs. Three-way repeated measures ANOVA
followed by Dunnett’s test. Data are reported as mean ± SE.
FIGURE 4 | %PPI ofWistar rats (WRs) and spontaneously hypertensive
rats (SHRs) treated with vehicle (VEH) or 15, 30, or 60 mg/kg
cannabidiol (CBD). *p < 0.001 compared toWRs. #p < 0.05 compared to
VEH group. Three-way repeated measures ANOVA followed by Dunnett’s
test. Data are reported as mean ± SE.
It could be argued that the deﬁcit in PPI in SHR might be a
consequence of the lower level of ASR displayed by this strain,
observed also in other studies (using WKY and SD rats as control
strains – Ferguson and Cada, 2003; van den Buuse, 2004). Never-
theless, this does not seem to be the case because the changes in
PPI induced by the drugs tested (increase or decrease – described
below) were not accompanied by changes in ASR levels (Table 1).
In addition, previous work in humans and rodents suggests that
lower baseline ASR is associated with higher PPI (Csomor et al.,
2008), which is opposite to what we observed in SHR. Therefore,
the reduced PPI in SHR is probably not due to their diminished
ASR. However, since ASR might inﬂuence PPI and the drugs
used could have induced subtle changes in ASR, the data were
re-analyzed with ASR as covariate (as suggested by Csomor et al.,
2008). The results of these analyses reinforce that the effects seen
on %PPI were not due to differences in ASR.
As commented above, several clinical and neurobiological ﬁnd-
ings suggest that cannabinoids and the endocannabinoid system
are implicated in schizophrenia (Leweke et al., 2004; D’Souza
et al., 2009). Our data show that cannabinoid drugs differentially
modulate the spontaneous deﬁcit of PPI presented by SHRs.
Concerning cannabinoid agonists, the interaction of 9-
tetrahydrocannabidiol (THC – the primary psychotropic con-
stituent of Cannabis sativa plant) with CB1 receptors seems
to be responsible for its psychotomimetic effects: induction
of a psychotic state in normal individuals, worsening of psy-
chotic symptoms of schizophrenic patients, and precipitation of
schizophrenia in vulnerable individuals (Ujike and Morita, 2004;
Sewell et al., 2010). Concerning speciﬁcally PPI, although one
clinical study did not observe alterations of PPI in drug-free
chronic cannabis users (Quednow et al., 2004), another showed
that chronic cannabis use in healthy individuals was associated
with attention-modulated reduction in PPI resembling the PPI
deﬁcit in schizophrenia (Kedzior and Martin-Iverson, 2006). In
addition, Mathias et al. (2011) did not observe differences in PPI
among adolescent cannabis users and controls, but they detected a
more rapid decline in PPI in frequent cannabis users. The authors
suggested that this could reﬂect a progressive reduction in the qual-
ity of information processing or sustained attention across the PPI
session.
With respect to rodent studies, treatment with the cannabi-
noid agonist WIN has been reported to disrupt sensorimotor
gating in systemically treated animals (Schneider and Koch, 2002;
Wegener et al., 2008), and after intra-prefrontal cortex and intra-
ventral hippocampus infusion (Wegener et al., 2008). It also
impaired recognition memory (Schneider and Koch, 2002), CFC
(Pamplona and Takahashi, 2006) and social interaction (Almeida
et al., in press) in rats. Consistent with this, our results showed
a trend toward a decrease in PPI in WRs treated with the low-
est dose of this compound (p = 0.095 – Figure 1). On the other
hand, in accordance the ability of WIN (1 mg/kg) to reverse the
basal PPI deﬁcit in SHRs (Figure 1), other studies have shown
that in animals with low basal PPI, such as phencyclidine-treated
rats (which induces “schizophrenia-like behaviors” – Gouzoulis-
Mayfrank et al., 2005) and psychosocially stressed mice (Brzozka
et al., 2011), treatment with WIN reverses this deﬁcit. In addi-
tion, other behavioral abnormalities induced by phencyclidine are
also reversed by this compound: impairments in novel object
recognition, and in social interaction (Spano et al., 2010), as
well as hyperlocomotion and anxiogenic behavior (Spano et al.,
2012). Consistent with this, another study from our group
demonstrates a beneﬁcial effect of WIN on the deﬁcit of social
interaction (mimicking the negative symptoms of schizophre-
nia – Sams-Dodd, 1998) presented by SHRs (Almeida et al.,
in press). Of note, the impairment of social interaction of
SHRs was attenuated only by atypical antipsychotics (Calzavara
et al., 2011). Finally, a study in a small group of schizophrenia
patients reported that treatment with synthetic THC (dronabi-
nol) improves the symptoms of the disease (Schwarcz et al.,
2009).
Taken as a whole, these data indicate that cannabinoid agonists
may present differential effects in controls and schizophrenia. This
observation might reﬂect dysfunctions of the endocannabinoid
system associated with schizophrenia that would also be displayed
by SHRs. In this sense, recently, our group showed that, as observed
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in schizophrenia patients (Dean et al., 2001; Zavitsanou et al., 2004;
Dalton et al., 2011), the SHR strain has a higher CB1 receptor
density in the prefrontal and anterior cingulate cortices when
compared to WRs (Levin et al., submitted).
Only one dose of WIN increased PPI in SHR. Several previous
studies have demonstrated similar biphasic effects of cannabinoid
agonists in different paradigms: low doses of these components
usually induce anxiolytic-like effects, while higher doses are anx-
iogenic or ineffective (Hill and Gorzalka, 2004; Viveros et al.,
2005; Fogaca et al., 2012). Moreover, a low dose (0.1 mg/kg) of
WIN stimulated motor activity, whereas a higher dose (1 mg/kg)
decreased this response (Polissidis et al., 2013). Similarly, in mice
submitted to a CFC task, THC exerted biphasic effects on fear-
coping strategies, with lower and higher doses favoring active
and passive responses, respectively (Metna-Laurent et al., 2012).
This proﬁle was also detected in clinical studies which observed
that low and moderate THC doses had anxiolytic and euphoric
properties, while higher doses produced anxiogenic responses (for
review, see Crippa et al., 2010). These variable effects, depending
on the dose, could be due to the wide neuroanatomical distribu-
tion of the endocannabinoid system and its modulatory effects on
both GABAergic and glutamatergic neurons (Moreira and Lutz,
2008; Fogaca et al., 2012; Metna-Laurent et al., 2012). This could
explain the inverted U-shaped dose–response curve of WIN on
PPI in SHRs (Figure 1), indicating that this dose-dependent effect
of cannabinoid agonists can also be seen for sensorimotor gating
deﬁcits.
Regarding the effects of the CB1 receptor antagonist rimona-
bant, our data revealed that the lowest dose (0.75mg/kg) worsened
the PPI deﬁcit presented by SHRs (Figure 2). On the other hand,
a recent study of our group showed that 3 mg/kg rimonabant was
able to reverse the deﬁcit in CFC in SHRs (Levin et al., 2012).
Any of the doses tested was able to modify the impairment in
social interaction and hyperlocomotion presented by this strain
(Almeida et al., in press). In this sense, the effects of CB1 antag-
onist seem to depend on the behavior evaluated and the dose
used.
Indeed, previous studies on the effects of rimonabant on
schizophrenia-like behaviors in animal models have shown con-
trasting results (Roser et al., 2010). While some studies showed
that rimonabant was able to counteract the disruption of PPI
produced by the N-methyl-D-aspartate (NMDA) antagonists,
phencyclidine and Dizocilpine (MK-801), and by the dopamine
agonist, apomorphine (Malone et al., 2004; Ballmaier et al., 2007),
others demonstrated that this drug did not reverse the PPI-
disruptive effects of apomorphine, amphetamine or MK-801,
nor the amphetamine-induced hyperactivity or stereotypy in rats
(Martin et al., 2003). Malone and Taylor (2006) demonstrated that
rimonabant reversed the THC-induced deﬁcits in PPI in socially
isolated rats (a long-term environmental manipulation used as
an animal model of schizophrenia – Weiss et al., 2000) but did
not reverse the isolation-induced deﬁcits in PPI per se (Malone
and Taylor, 2006). On the other hand, Ferrer et al. (2007) showed
that rimonabant potentiated stereotyped behavior induced by the
D1 and D2 dopamine agonists, (±)-1-phenyl-2,3,4,5-tetrahydro-
(1H)-3-benzazepine-7,8-diol (SKF-38393) and quinpirole (model
of positive symptoms – Ferrer et al., 2007). Finally, rimonabant
increased c-fos expression in mesocorticolimbic areas of rats
(Alonso et al., 1999), similar to typical and atypical antipsychotics
(Robertson and Fibiger, 1992). In addition, other CB1 antago-
nists (AM251 and AVE 1625) seem to reverse the cognitive deﬁcits
observed in pharmacological (Black et al., 2011; Guidali et al.,
2011) and neurodevelopmental (Zamberletti et al., 2012) animal
models of schizophrenia.
Interestingly, no effect was observed in WRs corroborating
previous data that show that rimonabant is not able to mod-
ify PPI under normal conditions (Martin et al., 2003; Ballmaier
et al., 2007), and reinforcing its speciﬁcity to “schizophrenia-like”
behaviors.
Clinical data with rimonabant are also conﬂicting. Some clin-
ical trials failed to show any antipsychotic effect of rimonabant
(Meltzer et al., 2004). On the other hand, in a small sample-size
study, rimonabant produced a signiﬁcant improvement in Brief
Psychiatric Rating Scale (BPRS) of schizophrenic patients (Kelly
et al., 2011). Conversely, Roser et al. (2011) showed that rimona-
bant produced a signiﬁcant deﬁcit in auditory sensory memory in
the ketamine model of schizophrenia.
Taken together, under our experimental conditions, the
cannabinoid receptor agonist WIN reversed PPI deﬁcits in SHRs,
whereas the CB1 antagonist rimonabant enhanced this deﬁcit,
indicating that the CB1 receptor might be involved in both basal
PPI deﬁcits seen here as well as in the modulatory effects of these
drugs. High densities of CB1 receptors have been found in brain
areas that regulate sensorimotor gating such as prefrontal cortex,
amygdala and hippocampus (Dissanayake et al., 2013). Moreover,
CB1 receptors have amodulatory role on speciﬁc neurotransmitter
systems, mainly glutamate, GABA and dopamine (Schlicker and
Kathmann, 2001), which have a critical role in the PPI processing.
Supporting the involvement of the endocannabinoid system
in schizophrenia, elevated anandamide levels in the cerebrospinal
ﬂuid (Leweke et al., 1999; Leweke et al., 2007; Koethe et al., 2009)
and plasma (De Marchi et al., 2003) of patients with schizophrenia
have been described. Moreover, studies showed that anandamide
levels were inversely correlated with psychotic symptoms (Giuf-
frida et al., 2004) and low levels of this endocannabinoid are a risk
factor for psychosis (Koethe et al., 2009). These studies suggest
that increased levels of anandamide in schizophrenia might play
a protective role to counteract the abnormalities in neurotrans-
mission during acute symptoms. Reinforcing this, Leweke et al.
(2012) showed that treatment with CBD resulted in a signiﬁcant
increase in anandamide levels, which was accompanied by clinical
improvement in schizophrenic patients.
In accordance with a protective role of anandamide, 5 mg/kg
AM404 (anandamide uptake inhibitor) was able to attenuate the
hyperlocomotion and impaired social interaction presented by
SHR (Almeida et al., in press). It is noteworthy that the same
range of doses used in that study and in the present one, was pre-
viously shown to increase anandamide levels in plasma (Giuffrida
et al., 2000) and brain regions (Bortolato et al., 2006) of rats. Local
injections of this compound also prevented the stereotypy and
hyperlocomotion induced by dopamine receptor agonist treat-
ment (Beltramo et al., 2000). Accordingly, Seillier et al. (2010)
demonstrated that fatty acid amidrohydrolase inhibitors reversed
PCP-induced social impairment. Nevertheless, in the present
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study AM404 did not modify the PPI deﬁcit in SHRs at any
dose (Figure 3). In this sense, the possible antipsychotic pro-
ﬁle of anandamide enhancers does not seem to include all the
“schizophrenia-like” behaviors.
In control WRs, AM404 did not modify PPI (Figure 3). In con-
trast, a previous study suggested thatAM404 (at similar doses used
in the present study) disrupted PPI (Fernandez-Espejo and Galan-
Rodriguez, 2004), increased locomotion and decreased social
interaction (Almeida et al., in press) in control strains. Differences
in the behavioral paradigms or rat strains might account for the
variable proﬁle of AM404 in control animals.
Cannabidiol, one of the major constituent of Cannabis sativa
(Grlie, 1976), is devoid of the typical psychotomimetic effects of
the plant (Zuardi, 2008; Crippa et al., 2010; Zuardi et al., 2010).
Several clinical studies revealed that this component does induce
central effects (Zuardi et al., 2010) including antipsychotic prop-
erties (Zuardi et al., 2006, 2010, 2012; Leweke et al., 2007). Several
clinical trials reveal that antipsychotic-like activity of CBD can
be demonstrated against psychotic symptoms induced in healthy
volunteers (Leweke et al., 2000; Zuardi et al., 2006; Borgwardt
et al., 2008; Bhattacharyya et al., 2009, 2010; Winton-Brown et al.,
2011), and in patients with Parkinson’s Disease (Zuardi et al.,
2009) or schizophrenia (Zuardi et al., 1995, 2006; Leweke et al.,
2007, 2012). Interestingly, these studies showed that CBD pro-
duces fewer (Leweke et al., 2007) or no (Zuardi et al., 1995, 2006,
2009; Leweke et al., 2012) side effects when compared to other
antipsychotics and suggest itmay be an effective andwell-tolerated
alternative treatment for schizophrenia (Zuardi,2008;Zuardi et al.,
2012; Bergamaschi et al., 2011).
This proﬁle is supported by several animal studies (Zuardi et al.,
2006; Roser and Haussleiter, 2012). CBD was able to reverse MK-
801-induced disruption of PPI (Long et al., 2006), inhibited the
hyperlocomotion induced by amphetamine and ketamine in mice
(Moreira and Guimaraes, 2005), and reversed the reduction in
social interaction produced by THC (Malone et al., 2009) and
MK-801 (Gururajan et al., 2011) in rats. Long et al. (2012) showed
that long-term CBD enhanced social interaction in neuregulin-1
mutant mice (a putative animal model of schizophrenia – Long
et al., 2012). Recently, our group showed that CBD was able
to reverse the deﬁcit in CFC presented by SHRs (Levin et al.,
2012). Moreover, similar to the atypical antipsychotic clozapine
(Robertson and Fibiger, 1992), CBD induced c-fos immunoreac-
tivity in the nucleus accumbens (but not in the striatum) of rats
(Guimaraes et al., 2004). The present results further support the
antipsychotic proﬁle of CBD since the dose of 30 mg/kg was able
to reverse the deﬁcit in PPI presented by SHRs.
Interestingly, contrary to the speciﬁcity of effect for PPI deﬁcits
in SHRs seen with WIN and rimonabant, the same dose of CBD
increased PPI in both WRs and SHRs (Figure 4). In this respect,
it might be suggested that the effects of CBD on molecular tar-
gets other than cannabinoid receptors (affected by WIN and
rimonabant) could account for its different proﬁle of action. The
molecular targets of CBD are not completely elucidated. Stud-
ies have suggested that CBD activates vaniloid receptors transient
receptor potential cation channel subfamilyVmember 1 (TRPV1),
inhibits the cellular uptake andhydrolysis of anandamide (Bisogno
et al., 2001), acts as an agonist at the 5HT1A receptor (Russo et al.,
2005), and acts as an indirect CB1/CB2 antagonist (Pertwee, 2008),
as well as an antagonist at the novel cannabinoid receptor G
protein-coupled receptor 55 (Campos et al., 2012). Although it
was not the aim of this study to reveal the neural mechanism
behind the effects of cannabinoid drugs on PPI, it is interesting
to note that the clinical improvement in schizophrenic patients
induced by CBD was accompanied by an increase in anandamide
levels (Leweke et al., 2012). However, our data suggest that the
enhancing effect of CBD on PPI does not seem to be due only
to an increase in anandamide levels, since AM404 (anandamide
uptake inhibitor) did not modify this response. In this context,
Bisogno et al. (2001) revealed that CBD is more potent in acti-
vating TRPV1 receptors than in inhibiting anandamide hydrolysis
and uptake. Strengthening the role of TRPV1 in the beneﬁcial
effect of CBD, the attenuation of MK-801-induced PPI deﬁcits is
prevented by pretreatment with capsazepine, a TRPV1 antagonist
(Long et al., 2006).
In conclusion, our results indicate that the sensorimotor gat-
ing impairment in SHRs can be modulated by cannabinoid drugs
pointing to these compounds as potential therapeutic strategies.
More speciﬁcally, the present study suggests a beneﬁcial property
of a direct cannabinoid receptor agonist (WIN55,212) and of CBD
on the PPI deﬁcits associated to schizophrenia.
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